Document is current
Any future updates will be listed below
-
Authors
Pietrzak, Michal
Yngve, Adam https://orcid.org/0000-0003-1012-7286
Hamilton, J. Paul https://orcid.org/0000-0001-7982-4659
Asratian, Anna
Gauffin, Emelie
Löfberg, Andreas
Gustavson, Sarah
Persson, Emil https://orcid.org/0000-0003-2994-0541
Capusan, Andrea J. https://orcid.org/0000-0003-1758-2206
Leggio, Lorenzo https://orcid.org/0000-0001-7284-8754
Perini, Irene https://orcid.org/0000-0002-5972-0913
Tinghög, Gustav https://orcid.org/0000-0002-8159-1249
Heilig, Markus
Boehme, Rebecca https://orcid.org/0000-0003-2803-3069
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
Marcus Wallenbergs Stiftelse för Internationellt Vetenskapligt Samarbete (2014.0187)
Vetenskapsrådet (2013-07434)
- License Information
-
More Information
Article History
Received: 28 September 2023
Revised: 1 February 2024
Accepted: 4 February 2024
First Online: 26 February 2024
Competing interests
: Author MH has received consulting fees, research support or other compensation from Indivior, Camurus, Molteni, BrainsWay, Aelis Farma, Lundbeck and Janssen Pharmaceuticals. MH is an associate editor of neuropsychopharmacology. Author AJC has received consulting fees from Indivior, Camurus, Lundbeck, DNEPharma. Remaining authors have declared that no conflict of interest exists.
